Trends of Pancreatic Cancer Incidence and Mortality in Changning District of Shanghai

FANG Jie; WANG Jie; LI Honglan; FENG Guoshan; WU Hua; JIANG Yufei; JIANG Yu; ZHANG Lei; ZHANG Yun; ZHOU Peng; XIA Qinghua; ZHAO Wensui; XIANG Yongbing

doi:10.3971/j.issn.1000-8578.2021.20.1116

Cancer Research on Prevention and Treatment > 2021 > 48(7): 727-732. > DOI: 10.3971/j.issn.1000-8578.2021.20.1116

FANG Jie, WANG Jie, LI Honglan, FENG Guoshan, WU Hua, JIANG Yufei, JIANG Yu, ZHANG Lei, ZHANG Yun, ZHOU Peng, XIA Qinghua, ZHAO Wensui, XIANG Yongbing. Trends of Pancreatic Cancer Incidence and Mortality in Changning District of Shanghai[J]. Cancer Research on Prevention and Treatment, 2021, 48(7): 727-732. DOI: 10.3971/j.issn.1000-8578.2021.20.1116

Citation:

PDF (4181 KB)

Trends of Pancreatic Cancer Incidence and Mortality in Changning District of Shanghai

1.
State Key Laboratory of Oncogenes and Related Genes & Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China
2.
Shanghai Changning District Center for Disease Control and Prevention, Shanghai 200051, China
3.
School of Public Health, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

Funding:

National Key Research and Development Program of China 2016YFC1302503

More Information

Corresponding author:
WANG Jie, E-mail: wangjiecat@163.com

LI Honglan, E-mail: hlli1974@163.com
Received Date: September 20, 2020
Revised Date: February 17, 2021
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To analyze the secular trends of pancreatic cancer incidence and mortality in Changning district of Shanghai from 1974 to 2013.
Methods
We calculated the age-standardized rates of incidence and mortality and the average annual percent changes for pancreatic cancer using Segi's world standard population and the data from Shanghai Cancer Registry. Age-period-cohort model was constructed to further assess the effect of age, diagnosis period and birth cohort on the secular trends of pancreatic cancer incidence and mortality.
Results
During 1974-2013, the age-standardized incidence and mortality rates were 6.49/10⁵ and 6.01/10⁵ in male, 4.83/10⁵ and 4.57/10⁵ in female, respectively. The age-standardized incidence was increased by 0.8% per year in male during past 40 years, while there was no change in mortality. The age-standardized incidence and mortality rates were increased by 1.6% and 1.3% per year in female. After adjusting the effects of diagnosis period and birth cohort, the incidence and mortality rates of pancreatic cancer increased by about 11% every 5 years older in both male and female. Diagnosis period and birth cohort had no statistical impact on the incidence and mortality of pancreatic cancer.
Conclusion
The age-standardized incidence of pancreatic cancer shows significantly rising trends during 1974-2013 in both male and female in Changning district of Shanghai, as well as the age-standardized mortality in female. The incidence and mortality rates also increase with age.
- Pancreatic cancer,
- Incidence,
- Mortality,
- Trend analysis,
- Age-period-cohort model

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (21)

References

[1]	Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors[J]. World J Oncol, 2019, 10(1): 10-27. doi: 10.14740/wjon1166
[2]	International Agency for Research on Cancer 2018[DB/OL]. [2020-3-29]. http://gco.iarc.fr/today.
[3]	Chen W, Zheng R, Baade PD, et al. Cancer Statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[4]	鲍萍萍, 吴春晓, 张敏璐, 等. 2015年上海市恶性肿瘤流行特征分析[J]. 中国癌症杂志, 2019, 29(2): 81-99. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ201902001.htm Bao PP, Wu CX, Zhang ML, et al. Report of cancer epidemiology in Shanghai, 2015[J]. Zhongguo Ai Zheng Za Zhi, 2019, 29(2): 81-99. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ201902001.htm
[5]	顾凯, 吴春晓, 鲍萍萍, 等. 上海市区1973至2007年胰腺癌的发病趋势[J]. 诊断学理论与实践, 2011, 10(4): 320-324. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDLS201104010.htm Gu K, Wu XC, Bao PP, et al. Trend in pancreatic cancer incidence in Shanghai urban area, 1973-2007[J]. Zhen Duan Xue Li Lun Yu Shi Jian, 2011, 10(4): 320-324. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDLS201104010.htm
[6]	上海市长宁区统计局课题组. 上海长宁区人口结构变迁与经济转型发展的关系研究[J]. 统计科学与实践, 2012, (9): 22-24. doi: 10.3969/j.issn.1674-8905.2012.09.006 Research group of Shanghai Changning District Bureau of Statistics. The relationship between population structure change and economic transformation and development in Changning District of Shanghai[J]. Tong Ji Ke Xue Yu Shi Jian, 2012, (9): 22-24. doi: 10.3969/j.issn.1674-8905.2012.09.006
[7]	张薇, 鲍萍萍, 项永兵. 上海市肿瘤登记工作的历史、发展和现况[J]. 上海预防医学, 2019, 31(9): 717-723. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYI201909003.htm Zhang W, Bao PP, Xiang YB. History, development and current status of cancer registration in Shanghai[J]. Shanghai Yu Fang Yi Xue, 2019, 31(9): 717-723. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYI201909003.htm
[8]	国家癌症中心. 中国肿瘤登记工作指导手册(2016)[M]. 北京: 人民卫生出版社, 2016: 33-75. National Cancer Center. Chinese Guideline for Cancer Registration[M]. Beijing: People's Medical Publishing House, 2016: 33-75.
[9]	Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates[J]. Stat Med, 2000, 19(3): 335-351. doi: 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z
[10]	Rosenberg PS, Check DP, Anderson WF. A web tool for age-period-cohort analysis of cancer incidence and mortality rates[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(11) : 2296-2302. doi: 10.1158/1055-9965.EPI-14-0300
[11]	黄照, 马文军. 年龄-时期-队列模型[J]. 华南预防医学, 2017, 43(4): 373-376. https://www.cnki.com.cn/Article/CJFDTOTAL-GDWF201704020.htm Hang Z, Ma WJ. Age-Period-Cohort Model[J]. Hua Nan Yu Fang Yi Xue, 2017, 43(4): 373-376. https://www.cnki.com.cn/Article/CJFDTOTAL-GDWF201704020.htm
[12]	陈万青, 王庆生, 张四维, 等. 2003-2007年中国胰腺癌发病与死亡分析[J]. 中国肿瘤, 2012, 11(4): 248-253. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201204002.htm Chen WQ, Wang QS, Zhang SW, et al. An Analysis of Incidence and Mortality of Pancreas Cancer in China, 2003-2007[J]. Zhongguo Zhong Liu, 2012, 11(4): 248-253. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201204002.htm
[13]	蔡慧, 徐光寰, 王珏, 等. 上海市原卢湾区2004-2011年消化系统常见肿瘤的发病和死亡趋势分析[J]. 中国临床医学, 2018, 25(4): 542-548. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201804007.htm Cai H, Xu GH, Wang J, et al. Analysis of incidence and mortality trends of common gastrointestinal cancers in Luwan District of Shanghai from 2004 to 2011[J]. Zhongguo Lin Chuang Yi Xue, 2018, 25(4): 542-548. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201804007.htm
[14]	毛铁波, 崔玖洁, 王理伟. 从基础到临床: 2019年胰腺癌研究进展[J]. 中国癌症杂志, 2020, 30(2): 81-89. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202002001.htm Mao TB, Cui JJ, Wang LW, Research progress in pancreatic cancer in 2019 from experimental study to clinical evaluation[J]. Zhongguo Ai Zheng Za Zhi, 2020, 30(2): 81-89. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202002001.htm
[15]	刘梦奇, 吉顺荣, 徐晓武, 等. 2019年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2020, 30(1): 1-10. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202001001.htm Liu MQ, Ji SR, Xu XW, et al. Advance in basic research, clinical diagnosis and treatment of pancreatic cancer in 2019[J]. Zhogguo Ai Zheng Za Zhi, 2020, 30(1): 1-10. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202001001.htm
[16]	马万里, 俞玲玲, 薛峰, 等. 浙江省嘉善县1988-2012年胰腺癌发病特征及趋势[J]. 中国肿瘤, 2015, 24(3): 181-185. doi: 10.3969/j.issn.1674-4136.2015.03.011 Ma WL, Yu LL, Xue F, et al. Characteristics and Trend of Pancreatic Cancer Incidence in Jiashan County, Zhejiang Province, 1988-2012[J]. Zhongguo Zhong Liu, 2015, 24(3): 181-185. doi: 10.3969/j.issn.1674-4136.2015.03.011
[17]	张永辉, 朱健, 严永峰, 等. 江苏省启东市1972-2016年胰腺癌死亡特征及变化趋势分析[J]. 中国肿瘤, 2020, 29(8): 586-591. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU202008005.htm Zhang YH, Zhu J, Yan YF, et al. Pancreatic Cancer Mortality and Trends in Qidong City, 1972-2016[J]. Zhongguo Zhong Liu, 2020, 29(8): 586-591. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU202008005.htm
[18]	傅卫. 上海城市健康影响评估机制与评估体系研究[J]. 科学发展, 2021, (1): 92-102. doi: 10.3969/j.issn.1674-6171.2021.01.012 Fu W. Study on Shanghai Urban Health Impact Assessment Mechanism and Assessment System[J]. Ke Xue Fa Zhan, 2021, (1): 92-102. doi: 10.3969/j.issn.1674-6171.2021.01.012
[19]	Shu XO, Li HL, Yang G, et al. Cohort profile: The Shanghai Men's Health Study[J]. Int J Epidemiol, 2015, 44(3): 810-818. doi: 10.1093/ije/dyv013
[20]	Zheng W, Chow WH, Yang G, et al. The Shanghai Women's Health Study: rationale, study design, and baseline characteristics[J]. Am J Epidemiol, 2005, 162(11): 1123-1131. doi: 10.1093/aje/kwi322
[21]	徐晓慧, 曾新颖, 王黎君, 等. 1990年与2017年中国胰腺癌疾病负担分析[J]. 中华流行病学杂志, 2019, 40(9): 1084-1088. doi: 10.3760/cma.j.issn.0254-6450.2019.09.012 Xu XH, Zeng XY, Wang LJ, et al. The disease burden of pancreatic cancer in China in 1990 and 2017[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2019, 40(9): 1084-1088. doi: 10.3760/cma.j.issn.0254-6450.2019.09.012

[1]	SHAN Baoen. Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era[J]. Cancer Research on Prevention and Treatment, 2023, 50(9): 833-841. DOI: 10.3971/j.issn.1000-8578.2023.22.1423
[2]	QIAO Shishi, KONG Tiandong, YU Dan, YANG Zhen, PAN Yanfeng, ZHAO Lingdi. A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 293-297. DOI: 10.3971/j.issn.1000-8578.2023.22.0852
[3]	YAN Guangning, YU Ling, LAI Xuwen, YE Danli, WANG Wei, WANG Zhuocai. Correlation Between PD-1/CTLA-4 Expressions with C linicopathological Features and Prognosis of Osteosarcoma Patients[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 63-68. DOI: 10.3971/j.issn.1000-8578.2023.22.0483
[4]	QI Lin, ZHANG Zhao, WANG Suyun, LIU Guimin, WANG Rui, FU Jianzhu, CHENG Zhiyong. Effect of Rapamycin on Exosomes and PD-1/PD-L1 in Human Erythroleukemia HEL Cells[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1021-1027. DOI: 10.3971/j.issn.1000-8578.2022.22.0188
[5]	CHANG Jinyi, WANG Wei, CAI Haifeng. Research Progress of PD-1/PD-L1 Inhibitor Combined with Trastuzumab in HER2-positive Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 965-969. DOI: 10.3971/j.issn.1000-8578.2022.21.1462
[6]	LAI Yanliang, GENG Yan, YANG Bingquan. Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1035-1040. DOI: 10.3971/j.issn.1000-8578.2021.21.0365
[7]	YU Lin, LI Guangping, ZHOU Changyu, FU Huaying. Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 794-798. DOI: 10.3971/j.issn.1000-8578.2021.20.1449
[8]	MA Yinjuan, YANG Xiaying, WANG Ying, WANG Xuan, PAN Yaozhu. Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 647-651. DOI: 10.3971/j.issn.1000-8578.2021.21.0108
[9]	WANG Yufeng, YAO Nan, WANG Jun, MIN Guangtao. Prognostic Role of PD-1 and PD-L1 Expression in Gastric Cancer Patients: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(5): 346-352. DOI: 10.3971/j.issn.1000-8578.2020.19.0950
[10]	ZOU Hanhui, Li Tao. Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(2): 141-146. DOI: 10.3971/j.issn.1000-8578.2020.19.0945

Cited By

Cited by

Periodical cited type(12)

1.	梅琪，袁牧，钱景瑜，刘若宇，谭玉林. 肝动脉化疗栓塞术联合卡瑞利珠及阿帕替尼治疗中晚期肝癌的安全性及临床疗效观察. 蚌埠医学院学报. 2024(01): 51-54+58 .
2.	李丽敏，王璐，曹阳博，刘栋利，陈鹏飞. 肝癌患者经导管动脉化疗栓塞后发生栓塞综合征的影响因素分析. 癌症进展. 2024(01): 72-75 .
3.	费睿成，亓民. PD-1单抗联合TACE对晚期原发性肝癌患者的治疗效果. 实用中西医结合临床. 2024(10): 16-19 .
4.	刘小梅，钟梅，刘浩，易军，王洪云. 晚期肝癌免疫相关治疗的获益和不良反应临床研究. 基层医学论坛. 2023(19): 20-22+35 .
5.	何晓锐，王淑红. 阿替利珠单抗联合贝伐珠单抗治疗晚期肝癌的临床效果. 临床医学研究与实践. 2023(27): 29-32 .
6.	陈方红，刘娱，边界. PD-1抑制剂治疗肝癌患者的临床疗效及ECOG-PS评分联合Child-Pugh分级对肿瘤超进展的预测价值. 广西医学. 2023(15): 1800-1806 .
7.	郭稳稳，程昌盛，吴燕，林文东，赖辉强，黄吉荣，龙高云. 安罗替尼治疗晚期肝癌的疗效及预后的影响因素. 临床与病理杂志. 2022(08): 1822-1828 .
8.	殷云飞，鲁邱阳. 抗PD-1单抗对中晚期肝癌患者近期疗效、外周血T淋巴细胞亚群指标的影响. 中国医学创新. 2021(13): 19-22 .
9.	李冰妍，陈林会，郑颖娟，梁天嵩，杨道科. 程序性死亡受体1抑制剂治疗远处转移鼻咽癌疗效观察. 肿瘤基础与临床. 2021(03): 207-211 .
10.	朱风婷，曾江正，姜靖雯，陈学武，张慧. 卡瑞利珠单抗联合射频消融术及FOLFOX方案治疗原发性肝癌疗效研究. 中国药业. 2021(15): 38-41 .
11.	王俊旗，徐锋. 程序性死亡受体1及其配体PD-L1、细胞毒性T淋巴细胞相关抗原4抑制剂在晚期肝癌治疗中的进展. 中华普通外科学文献(电子版). 2021(04): 304-308 .
12.	鄢清元，熊巍，杨文平. 晚期肝癌患者索拉非尼分子靶向治疗的有效性及对疾病控制率的影响研究. 中国医学创新. 2021(29): 173-177 .

Other cited types(0)

Figures(2) / Tables(2)

Get Citation

PDF

XML

Article views (1343) PDF downloads (457) Cited by(12)

Turn off MathJax

Article Contents

Abstract

References

Trends of Pancreatic Cancer Incidence and Mortality in Changning District of Shanghai